-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MNsVLayS8dCLwP9EF+1tlXjlIT13pOaxsYzpKmebz+GkN9MFGiXd8OY8QmHsJEf1 Vc+ua2gC/IJ2TpiRTjOCXg== /in/edgar/work/20000803/0001074140-00-000348/0001074140-00-000348.txt : 20000921 0001074140-00-000348.hdr.sgml : 20000921 ACCESSION NUMBER: 0001074140-00-000348 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20000710 ITEM INFORMATION: ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 20000803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SANGUI BIOTECH INTERNATIONAL INC CENTRAL INDEX KEY: 0001104280 STANDARD INDUSTRIAL CLASSIFICATION: [9995 ] IRS NUMBER: 841330732 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: SEC FILE NUMBER: 000-29233 FILM NUMBER: 685069 BUSINESS ADDRESS: STREET 1: 1508 BROOKHOLLOW DRIVE STREET 2: SUITE 354 CITY: SANTA ANA STATE: CA ZIP: 92705 BUSINESS PHONE: 7144297807 MAIL ADDRESS: STREET 1: 1508 BROOKHOLLOW DRIVE STREET 2: SUITE 354 CITY: SANTA ANA STATE: CA ZIP: 92705 FORMER COMPANY: FORMER CONFORMED NAME: FELNAM INVESTMENTS INC DATE OF NAME CHANGE: 20000127 8-K/A 1 0001.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 10, 2000 --------------- SANGUI BIOTECH INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-21271 84-1330732 ---------------- ------------------------ (Commission File Number) (IRS Employer Identification No.) 1508 BROOKHOLLOW DRIVE, SUITE 354 SANTA ANA, CALIFORNIA 92705 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) (714) 429-7807 ------------------------- Registrant's telephone number, including area code: Not applicable --------------------------------- (Former name, address and telephone number) 1 ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT Effective July 10, 2000, the Board of Directors of the Company approved the engagement of Corbin & Wertz Certified Public Accountants as its independent auditors for the fiscal year ending June 30, 2000 to replace Ernst & Young Deutsche Allgemeine Treuhand AG Wirtschaftsprufungsgesellschaft (Ernst & Young) who declined to stand for reelection. The report of Ernst & Young on the Company's financial statements for the six months ended June 30, 1999 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. In connection with the audit of the Company's financial statements for the six months ending June 30, 1999, and in the subsequent interim period preceding the date Ernst & Young declined to stand for reelection, there were no disagreements with Ernst & Young on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures which, if not resolved to the satisfaction of Ernst & Young would have caused Ernst & Young to make reference to the matter in their report. The Company has requested Ernst & Young to furnish it a letter addressed to the Commission stating whether it agrees with the above statements. A copy of that letter, dated August 3, 2000 is filed as Exhibit 1 to this Form 8-K/A. EXHIBITS 16.1 LETTER DATED AUGUST 3, 2000, FROM ERNST & YOUNG REGARDING ITS CONCURRENCE WITH THE STATEMENTS MADE BY THE REGISTRANT IN THIS CURRENT REPORT. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. SANGUI BIOTECH INTERNATIONAL, INC. /s/ Wolfgang Barnikol ---------------------------------- President and Chief Executive Officer Date: August 3, 2000 EX-16.1 2 0002.txt August 3, 2000 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549 Gentlemen: We have read Item 4 of Form 8-K/A dated August 3, 2000 for an event on July 10, 2000, of Sangui Biotech International Inc. and are in agreement with the statements contained in the 2nd and 3rd paragraphs on page 2 therein. We have no basis to agree or disagree with other statements of the registrant contained therein. Sincerely, /s/ Ernst & Young Deutsche Allgemeine Treuhand AG Wirtschaftsprufungsgesellschaft -----END PRIVACY-ENHANCED MESSAGE-----